Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-03-08
2011-03-08
Gussow, Anne M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S138100, C435S007100
Reexamination Certificate
active
07901682
ABSTRACT:
Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that bind sphingolipids or sphingolipid metabolites. In one embodiment the agent is an antibody or antibody derivative. In some embodiments, the agent is a receptor of a sphingolipid or a sphingolipid metabolite. Also disclosed are methods for identifying and isolating therapeutic agents.
REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4816450 (1989-03-01), Bell et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 5079263 (1992-01-01), Zeeck et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248824 (1993-09-01), Igrashi et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5369030 (1994-11-01), Hannun et al.
patent: 5391800 (1995-02-01), Igrashi et al.
patent: 5430169 (1995-07-01), Boumendiel et al.
patent: 5444087 (1995-08-01), Patel et al.
patent: 5585476 (1996-12-01), MacLennan et al.
patent: 5627171 (1997-05-01), Park et al.
patent: 5663404 (1997-09-01), Igarashi et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5677337 (1997-10-01), Wei et al.
patent: 5851782 (1998-12-01), Hannun et al.
patent: 5877167 (1999-03-01), Igarashi et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 5929039 (1999-07-01), Woodcock et al.
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6057126 (2000-05-01), Munroe et al.
patent: 6130067 (2000-10-01), Tsui
patent: 6140060 (2000-10-01), Chun et al.
patent: 6187562 (2001-02-01), Duckworth et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6284798 (2001-09-01), Amtmann et al.
patent: 6306911 (2001-10-01), Wachter et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6352844 (2002-03-01), Maurer et al.
patent: 6423527 (2002-07-01), Saba et al.
patent: 6534322 (2003-03-01), Sabbadini
patent: 6534323 (2003-03-01), Sabbadini
patent: 6610835 (2003-08-01), Liotta et al.
patent: 6613322 (2003-09-01), Tabas et al.
patent: 6649362 (2003-11-01), Gamble et al.
patent: 6858383 (2005-02-01), Sabbadini
patent: 6881546 (2005-04-01), Sabbadini
patent: 7169390 (2007-01-01), Sabbadini
patent: 2001/0041688 (2001-11-01), Waeber et al.
patent: 2002/0150582 (2002-10-01), Friedrichs et al.
patent: 2003/0125533 (2003-07-01), Kossida et al.
patent: 2003/0219782 (2003-11-01), Saba et al.
patent: 0173648 (1986-03-01), None
patent: 0173663 (1986-03-01), None
patent: 09-110722 (1987-04-01), None
patent: 2000-293181 (2000-10-01), None
patent: WO 97/44019 (1997-11-01), None
patent: WO 98/03529 (1998-01-01), None
patent: WO 98/28445 (1998-07-01), None
patent: WO 98/40349 (1998-09-01), None
patent: WO 98/57179 (1998-12-01), None
patent: WO 99/07855 (1999-02-01), None
patent: WO 99/12890 (1999-03-01), None
patent: WO 99/16888 (1999-04-01), None
patent: WO 99/33972 (1999-07-01), None
patent: WO 99/38983 (1999-08-01), None
patent: WO 99/41265 (1999-08-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/00593 (2000-01-01), None
patent: WO 00/21919 (2000-04-01), None
patent: WO 00/40262 (2000-07-01), None
patent: WO 00/52173 (2000-09-01), None
patent: WO 00/56135 (2000-09-01), None
patent: WO 00/58448 (2000-10-01), None
patent: WO 00/58491 (2000-10-01), None
patent: WO 00/59517 (2000-10-01), None
patent: WO 00/70028 (2000-11-01), None
patent: WO 00/72833 (2000-12-01), None
patent: WO 01/04108 (2001-01-01), None
patent: WO 01/04139 (2001-01-01), None
patent: WO 01/07418 (2001-02-01), None
patent: WO 01/31029 (2001-05-01), None
patent: WO 01/38295 (2001-05-01), None
patent: WO 01/55410 (2001-08-01), None
patent: WO 01/57057 (2001-08-01), None
patent: WO 01/60990 (2001-08-01), None
patent: WO 01/71045 (2001-09-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 01/80903 (2001-11-01), None
patent: WO 01/85953 (2001-11-01), None
Granziero, Krajewski, Farness, Yuan, Courtney, Jackson, Peterson, and Vitiello. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. European Journal of Immunology, 1999. vol. 29, pp. 1127-1138.
Byers. What can randomized control trials tell us about nutrition and cancer prevention? CA Cancer Journal, 1999. vol. 49, pp. 353-361.
Wright, Shin, and Morrison. Genetically engineered antibodies: progress and prospects. Critical Reviews in Immunology, 1992. vol. 12, pp. 125-168.
MSNBC News Services. Mixed results on new cancer drug. Nov. 9, 2000.
Gura. Systems for identifying new drugs are often faulty. Science, 1997. vol. 278, pp. 1041-1042.
Sabbadini. Targeting sphingosine-1-phosphate for cancer therapy. British Journal of Cancer, 2006. vol. 95, pp. 1131-1135.
Forni, Lollini, Musiani, and Colombo. Immunoprevention of cancer: is the time ripe? Cancer Research, 2000. vol. 60, pp. 2571-2575.
De Gruijl and Curiel. Cancer vaccine strategies get bigger and better. Nature Medicine, 1999. vol. 5, pp. 1124-1125.
Chatterjee, Foon, and Kohler. Idiotypic antibody immunotherapy of cancer. Cancer Immunology Immunotherapy, 1994. vol. 38, pp. 75-82.
Bodey, Bodey, Siegel, and Kaiser. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Research, 2000. vol. 20, pp. 2665-2676.
Abe et al., “Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and tumor cell growth,”J. Lipid Res. 36(3):611-621 (1995).
Abe et al., “Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase,”Kidney Int. 57(2):446-454 (2000).
Abe et al., “Use of Sulfobutyl Ether-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthase Inhibitors,”Anal. Biochem. 287(2):344-347 (2000).
Ambati, “Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies,”Surv. Ophthalmol. 48(3):257-293 (2003) (Abstract Only).
An et al., “Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids,”FEBS Letts. 417(3):279-282 (1997).
An et al., “Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic Acid,”J. Biol. Chem. 273(14):7906-7910 (1998).
An et al., “Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5,”J. Biol. Chem. 275(1):288-296 (2000).
Ancellin et al., “Extracelluar export of sphingosine kinase-1 enzyme: Sphingosine 1 phosphate generation and the induction of angiogenic vascular maturation,”J. Biol. Chem. 277(8):6667-6675 (2001).
Andrieu-Abadie et al., “L-camitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation,”FASEB J. 13(12):1501-1510 (1999).
Arenz et al., “Synthese des ersten selektiven irreverilben Inhibitors der neutralen Sphingomyelinase,”Angew Chem. 112:1498-1500 (2000) (GERMAN); “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Angew. Chem. Int. Ed. 39(8):1440-1442 (2000) (English Equivalent).
Arenz et al., “Manumycin A and its Analogues Are Irreversible Inhibitors of Neutral Sphingomyelinase,”Chem. Biochem. 2(2):141-143 (2001).
Arenz et al., “Synthesis and Biochemical Investigation of Scyphostatin Analogues as Inhibitors of Neutral Sphingomyelinase,”Bioorg. Medicinal Chem. 9(11):2901-2904 (2001).
Arenz et al., “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Eur. J. Org. Chem. 2001(1):137-140 (2001).
Ariga et al., “Role of Sphingolipid-mediated cell death in neurodegenerative diseases,”J. Lip. Res. 39(1):1-16 (1998).
Bajjalieh at al., “Ceramide Kinase,&#x
BioTechnology Law Group
Chambers Daniel M.
Gussow Anne M.
Lpath, Inc.
LandOfFree
Compositions and methods for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2748205